[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Daiichi Sankyo's lung cancer treatment secures FDA approval, but legal issues surrounding the Fortis acquisition are causing social media buzz.
Daiichi Sankyo Company Limited is a global pharmaceutical company.
Price 24-Hour Chart Data
The price action is likely uncertain due to mixed sentiment. Positive news regarding the lung cancer treatment approval is balanced by negative sentiment related to the Fortis acquisition dispute.
1-Year High: $XXXXX on 2024-10-30
1-Year Low: $XXXXX on 2025-04-17
AltRank 24-Hour Chart Data
Daiichi Sankyo Company Limited is currently AltRank #undefined based on combined combined social and market metrics
Daily Average: XXX
1-Year High: XXXXX on 2025-03-10
1-Year Low: XXX on 2025-01-21
Galaxy Score 24-Hour Chart Data
Current Value: XX
Daily Average: XX
1-Year High: XX on 2025-02-25
1-Year Low: XX on 2024-09-01
Engagements 24-Hour Chart Data
Current Value: XXX
Daily Average: XXXXXX
1 Week: XXXXXXX +118%
1 Month: XXXXXXX +322%
6 Months: XXXXXXXXX -XX%
1 Year: XXXXXXXXX +492%
1-Year High: XXXXXXX on 2024-09-12
1-Year Low: X on 2024-09-02
Social Network | X | YouTube | News | |
---|---|---|---|---|
Engagements | X | XXX | X | X |
Mentions 24-Hour Chart Data
Current Value: XX
Daily Average: XX
1 Week: XX +46%
1 Month: XXX -X%
6 Months: XXX +64%
1 Year: XXX +79%
1-Year High: XX on 2025-07-04
1-Year Low: X on 2024-07-27
Social Network | X | YouTube | News | |
---|---|---|---|---|
Mentions | X | XX | X | X |
Creators 24-Hour Chart Data
XX unique social accounts have posts mentioning Daiichi Sankyo Company Limited in the last XX hours which is up XXXX% from XX in the previous XX hours
Daily Average: XX
1 Week: XX +34%
1 Month: XXX -XXXX%
6 Months: XXX +65%
1 Year: XXX +80%
1-Year High: XX on 2025-07-04
1-Year Low: X on 2024-07-27
The most influential creators that mention Daiichi Sankyo Company Limited in the last XX hours
Creator | Rank | Followers | Posts | Engagements |
---|---|---|---|---|
@daiichisankyous | X | XXX | X | XXX |
Sentiment 24-Hour Chart Data
Current Value: XX%
Daily Average: XX%
1 Week: XXX% no change
1 Month: XXX% +10%
6 Months: XXX% no change
1 Year: XXX% no change
1-Year High: XXX% on 2024-07-29
1-Year Low: XX% on 2025-05-23
Most Supportive Themes
Most Critical Themes
Network engagement breakdown:
Network | Positive | % | Neutral | % | Negative | % |
---|---|---|---|---|---|---|
X | X% | X | X% | X | X% | |
X | XX | XX% | XXX | XX% | XX | X% |
YouTube | X | X% | X | X% | X | X% |
News | X | X% | X | X% | X | X% |
Total | XX | XX% | XXX | XX% | XX | X% |
Market Cap 24-Hour Chart Data
Current Value: $undefined
Daily Average: $XXXXXXXXXXXXXXXXX
1-Year High: $XXXXXXXXXXXXXXXXXX on 2024-07-31
1-Year Low: $XXXXXXXXXXXXXXXXX on 2025-02-20
Top assets mentioned In the posts about Daiichi Sankyo Company Limited in the last XX hours
Pfizer, Inc. (PFE) AstraZeneca PLC (AZN) Novartis AG (NVS) Merck & Co., Inc. (MRK)
Top topics mentioned In the posts about Daiichi Sankyo Company Limited in the last XX hours
$6417t, $8750t, drugs, $pfe, crafts, $baynsg, $azn, breakthrough, united states, $espr, jst, par, bal, $500m, le, novartis, money, $nwbo, help the, johnson and johnson, stocks healthcare, $2269t, $8986t, $8601t, lever, $7974t, marking, $47m, belgium, singapore, $302440ks, samsung, japan, astellas pharma, $mrk, auction, coins healthcare, dra, aos
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"@lifeisblank21 @jfineman company worth $2b+ current stock price a joke Debt looks inflated bc they sold EU royalty rights for $330m+ a year ago but they have to account for the $500m OMERS will receive from EU partner Daiichi Sankyo on their bal sheet even though they aren't paying it.DS is"
@Aridian397 on X 2025-07-24 18:56:17 UTC XXX followers, XX engagements
"Study is objective using EHR data from X systems; promotes vaccination based on findings. Weaknesses: observational (residual confounding misclassification) site heterogeneity limited generalizability small subtype samples no treatment-vaccination timing underreported diagnoses. Pharma links: Dr Reckamp received personal fees from AstraZeneca Daiichi Sankyo Genentech GlaxoSmithKline Janssen Merus Novartis Novocure Pfizer; institutional funding from Genentech Blueprint Daiichi Sankyo Elevation Oncology Janssen"
@lesdeuxbernois on X 2025-07-24 13:03:28 UTC 1056 followers, XXX engagements
"Pleased to welcome Daiichi Sankyo as a Gold Sponsor of #APGCS2025 Join us Aug XX in Singapore as we explore the future of GI oncology with global leaders. 🔗 Register: #DaiichiSankyo #GIcancer #OncologyCare #GoldSponsor"
@apgcs_summit on X 2025-07-24 11:34:43 UTC XXX followers, XX engagements
"@lonnibesancon article produit par les petites pu. d'Aztrazeneca et Pfizer . Juste un article pour te torcher avec "Dr Reckamp reported receiving personal fees from AstraZeneca Daiichi Sankyo Genentech GlaxoSmithKline Janssen Merus Novartis Novocure and Pfizer""
@frachanl on X 2025-07-23 06:52:46 UTC XXX followers, XX engagements